Philip Clarke

List of Publications by Year
in descending order

167 papers	7,291 citations	76031 42 h-index	75989 78 g-index
171 all docs	171 docs citations	171 times ranked	10058 citing authors

#	ARTICLE	IF	CITATIONS
1	The Value of Genomic Testing: A Contingent Valuation Across Six Child- and Adult-Onset Genetic Conditions. Pharmacoeconomics, 2022, 40, 215-223.	1.7	6
2	Eliciting risk preferences that predict risky health behavior: A comparison of two approaches. Health Economics (United Kingdom), 2022, 31, 836-858.	0.8	10
3	Relative contribution of trends in myocardial infarction event rates and case fatality to declines in mortality: an international comparative study of 1Â·95 million events in 80Â·4 million people in four countries. Lancet Public Health, The, 2022, 7, e229-e239.	4.7	23
4	The QALY at 50: One story many voices. Social Science and Medicine, 2022, 296, 114653.	1.8	6
5	Exploring Structural Uncertainty and Impact of Health State Utility Values on Lifetime Outcomes in Diabetes Economic Simulation Models: Findings from the Ninth Mount Hood Diabetes Quality-of-Life Challenge. Medical Decision Making, 2022, 42, 599-611.	1.2	5
6	Patient and clinician characteristics and preferences for increasing participation in placebo surgery trials: a scoping review of attributes to inform a discrete choice experiment. Trials, 2022, 23, 296.	0.7	1
7	Reply to Spreco et al.: Perceived corruption and preferences for COVID-19 vaccine allocations. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2201847119.	3.3	1
8	Survival, Dependency, and Health-Related Quality of Life in Patients With Ruptured Intracranial Aneurysm: 10-Year Follow-up of the United Kingdom Cohort of the International Subarachnoid Aneurysm Trial. Neurosurgery, 2021, 88, 252-260.	0.6	18
9	Impact of Comorbid Conditions on Healthcare Expenditure and Work-related Outcomes in Patients With Rheumatoid Arthritis. Journal of Rheumatology, 2021, 48, 1221-1229.	1.0	5
10	Public opinion on global rollout of COVID-19 vaccines. Nature Medicine, 2021, 27, 935-936.	15.2	30
11	Lessons from the pandemic on the value of research infrastructure. Health Research Policy and Systems, 2021, 19, 54.	1.1	10
12	Population norms for quality adjusted life years for the United States of America, China, the United Kingdom and Australia. Health Economics (United Kingdom), 2021, 30, 1950-1977.	0.8	8
13	Development of a life expectancy table for individuals with type 1 diabetes. Diabetologia, 2021, 64, 2228-2236.	2.9	10
14	The effects of self-assessed health: Dealing with and understanding misclassification bias. Journal of Health Economics, 2021, 78, 102463.	1.3	2
15	Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90). Diabetic Medicine, 2021, 38, e14656.	1.2	10
16	Excess cost of care associated with sepsis in cancer patients: Results from a population-based case-control matched cohort. PLoS ONE, 2021, 16, e0255107.	1.1	4
17	Weight loss interventions on healthâ€related quality of life in those with moderate to severe obesity: Findings from an individual patient data metaâ€analysis of randomized trials. Obesity Reviews, 2021, 22, e13317.	3.1	10
18	Citizens from 13 countries share similar preferences for COVID-19 vaccine allocation priorities. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	34

#	Article	IF	Citations
19	Is There Broad-Based Support in High-Income Countries for COVID-19 Vaccine Donation? Evidence from Seven Countries. Applied Health Economics and Health Policy, 2021, , 1.	1.0	3
20	Disease-related income and economic productivity loss in New Zealand: A longitudinal analysis of linked individual-level data. PLoS Medicine, 2021, 18, e1003848.	3.9	8
21	Costâ€effectiveness of professionalâ€mode flash glucose monitoring in general practice among adults with type 2 diabetes: Evidence from the GPâ€OSMOTIC trial. Diabetic Medicine, 2021, , e14747.	1.2	1
22	Development and Use of Prediction Models for Classification of Cardiovascular Risk of Remote Indigenous Australians. Heart Lung and Circulation, 2020, 29, 374-383.	0.2	5
23	Defining and measuring health poverty. Social Science and Medicine, 2020, 244, 112633.	1.8	32
24	Association of technologically assisted integrated care with clinical outcomes in type 2 diabetes in Hong Kong using the prospective JADE Program: A retrospective cohort analysis. PLoS Medicine, 2020, 17, e1003367.	3.9	24
25	Patient-reported outcome measures (PROMs): can they be used to guide patient-centered care and optimize outcomes in total knee replacement?. Quality of Life Research, 2020, 29, 3273-3283.	1.5	21
26	The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. Lancet, The, 2020, 396, 2019-2082.	6.3	327
27	Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge. Value in Health, 2020, 23, 1163-1170.	0.1	32
28	How Should a Safe and Effective COVID-19 Vaccine be Allocated? Health Economists Need to be Ready to Take the Baton. PharmacoEconomics - Open, 2020, 4, 557-561.	0.9	24
29	Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data. Medical Decision Making, 2020, 40, 460-473.	1.2	15
30	A Patient-Level Model to Estimate Lifetime Health Outcomes of Patients With Type 1 Diabetes. Diabetes Care, 2020, 43, 1741-1749.	4.3	12
31	Effects of Allopurinol on the Progression of Chronic Kidney Disease. New England Journal of Medicine, 2020, 382, 2504-2513.	13.9	281
32	Co-Morbidities and Sex Differences in Long-Term Quality-of-Life Outcomes among Patients with and without Diabetes after Total Knee Replacement: Five-Year Data from Registry Study. Journal of Clinical Medicine, 2020, 9, 19.	1.0	6
33	Selfâ€rated health scores predict mortality among people with type 2 diabetes differently across three different country groupings: findings from the ADVANCE and ADVANCEâ€ON trials. Diabetic Medicine, 2020, 37, 1379-1385.	1.2	9
34	Registered Reports: Time to Radically Rethink Peer Review in Health Economics. PharmacoEconomics - Open, 2020, 4, 1-4.	0.9	5
35	The acceptability of using a lottery to allocate research funding: a survey of applicants. Research Integrity and Peer Review, 2020, 5, 3.	2.2	37
36	Group Testing for SARS-CoV-2: Forward to the Past?. PharmacoEconomics - Open, 2020, 4, 207-210.	0.9	15

#	ARTICLE	IF	CITATIONS
37	Exploring the Impact of Quality of Life on Survival: A Case Study in Total Knee Replacement Surgery. Medical Decision Making, 2020, 40, 302-313.	1.2	2
38	The impact of Medicare part D on income-related inequality in pharmaceutical expenditure. International Journal for Equity in Health, 2019, 18, 57.	1.5	2
39	The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood. Pharmacoeconomics, 2019, 37, 1305-1312.	1.7	28
40	Transparency in Decision Modelling: What, Why, Who and How?. Pharmacoeconomics, 2019, 37, 1355-1369.	1.7	28
41	Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients. Pharmacoeconomics, 2019, 37, 931-941.	1.7	7
42	Excess Burden of Mental Illness and Hospitalization in Young-Onset Type 2 Diabetes. Annals of Internal Medicine, 2019, 170, 145.	2.0	53
43	Health system costs for individual and comorbid noncommunicable diseases: An analysis of publicly funded health events from New Zealand. PLoS Medicine, 2019, 16, e1002716.	3.9	44
44	Subgroup Decomposability of Income‐Related Inequality of Health, with an Application to Australia. Economic Record, 2018, 94, 39-50.	0.2	7
45	Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. Value in Health, 2018, 21, 724-731.	0.1	63
46	Longevity of outstanding sporting achievers: Mind versus muscle. PLoS ONE, 2018, 13, e0196938.	1.1	7
47	Aspects of Multicomponent Integrated Care Promote Sustained Improvement in Surrogate Clinical Outcomes: A Systematic Review and Meta-analysis. Diabetes Care, 2018, 41, 1312-1320.	4.3	81
48	Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes. Annals of Internal Medicine, 2018, 168, 170.	2.0	28
49	Accuracy of patient recall for self‐reported doctor visits: Is shorter recall better?. Health Economics (United Kingdom), 2018, 27, 1684-1698.	0.8	34
50	GP-OSMOTIC trial protocol: an individually randomised controlled trial to determine the effect of retrospective continuous glucose monitoring (r-CGM) on HbA1c in adults with type 2 diabetes in general practice. BMJ Open, 2018, 8, e021435.	0.8	8
51	Born equal? The distribution of government Medicare spending for children. Social Science and Medicine, 2018, 208, 50-54.	1.8	21
52	Treatment gaps and potential cardiovascular risk reduction from expanded statin use in the US and England. PLoS ONE, 2018, 13, e0190688.	1.1	15
53	Association between serum hepcidin‐25 and primary resistance to erythropoiesis‐stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. Nephrology, 2017, 22, 548-554.	0.7	11
54	Growth of linked hospital data use in Australia: a systematic review. Australian Health Review, 2017, 41, 394.	0.5	35

#	Article	IF	Citations
55	The Impact of Regression to the Mean on Economic Evaluation in Quasiâ€Experimental Preâ€"Post Studies: The Example of Total Knee Replacement Using Data from the Osteoarthritis Initiative. Health Economics (United Kingdom), 2017, 26, e35-e51.	0.8	11
56	Cost-effectiveness of gastric band surgery for overweight but not obese adults with type 2 diabetes in the U.S.. Journal of Diabetes and Its Complications, 2017, 31, 1139-1144.	1.2	10
57	Using administrative data to look at changes in the level and distribution of out-of-pocket medical expenditure: An example using Medicare data from Australia. Health Policy, 2017, 121, 426-433.	1.4	16
58	Australian general practitioners initiate statin therapy primarily on the basis of lipid levels; New Zealand general practitioners use absolute risk. Health Policy, 2017, 121, 1233-1239.	1.4	4
59	Associations between maternal size and health outcomes for women undergoing caesarean section: a multicentre prospective observational study (The MUM SIZE Study). BMJ Open, 2017, 7, e015630.	0.8	10
60	On the measurement of socioeconomic inequality of health between countries. Journal of Economic Inequality, 2017, 15, 175-193.	2.0	4
61	Predicting the Long-Term Gains in Health-Related Quality of Life After Total Knee Arthroplasty. Journal of Arthroplasty, 2017, 32, 395-401.e2.	1.5	28
62	How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus?Âa Systematic Review. Pharmacoeconomics, 2017, 35, 319-329.	1.7	13
63	Cost-effectiveness of artemisininâ€"naphthoquine versus artemetherâ€"lumefantrine for the treatment of uncomplicated malaria in Papua New Guinean children. Malaria Journal, 2017, 16, 438.	0.8	1
64	Using democracy to award research funding: an observational study. Research Integrity and Peer Review, 2017, 2, 16.	2.2	5
65	Costâ€effectiveness of screening for anal cancer using regular digital anoâ€rectal examinations in men who have sex with men living with HIV. Journal of the International AIDS Society, 2016, 19, 20514.	1.2	30
66	Expenditures and Prices of Antihyperglycemic Medications in the United States: 2002-2013. JAMA - Journal of the American Medical Association, 2016, 315, 1400.	3.8	111
67	Recent trends in life expectancy for people with type 1 diabetes in Sweden. Diabetologia, 2016, 59, 1167-1176.	2.9	81
68	The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. Redox Report, 2016, 21, 14-23.	1.4	8
69	Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report. Value in Health, 2016, 19, 704-719.	0.1	101
70	Using Patient-Reported Outcomes for Economic Evaluation: Getting the Timing Right. Value in Health, 2016, 19, 945-950.	0.1	24
71	Cost of Antihyperglycemic Medications in the United Statesâ€"Reply. JAMA - Journal of the American Medical Association, 2016, 316, 665.	3.8	0
72	Alexander Sutherland: A Forgotten Pioneer of Health Economics in Australia?. Australian Economic Review, 2016, 49, 169-173.	0.4	0

#	ARTICLE	IF	CITATIONS
73	Do Model-Based Studies in Chronic Obstructive Pulmonary Disease Measure Correct Values of Utility? A Meta-Analysis. Value in Health, 2016, 19, 363-373.	0.1	7
74	Changes in Quality of Life Associated with Complications of Diabetes: Results from the ADVANCE Study. Value in Health, 2016, 19, 36-41.	0.1	83
75	Health State Utility Value in Chronic Obstructive Pulmonary Disease (COPD); The Challenge of Heterogeneity: A Systematic Review and Meta-Analysis. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2016, 13, 380-398.	0.7	16
76	A randomized trial of fellowships for early career researchers finds a high reliability in funding decisions. Journal of Clinical Epidemiology, 2016, 69, 147-151.	2.4	12
77	Using Classification and Regression Trees (CART) to Identify Prescribing Thresholds for Cardiovascular Disease. Pharmacoeconomics, 2016, 34, 195-205.	1.7	21
78	Long-term Disability Associated With War-related Experience Among Vietnam Veterans. Medical Care, 2015, 53, 401-408.	1.1	10
79	Measuring the Progressivity of the Pharmaceutical Benefits Scheme. Australian Economic Review, 2015, 48, 122-132.	0.4	6
80	The impact of a streamlined funding application process on application time: two cross-sectional surveys of Australian researchers. BMJ Open, 2015, 5, e006912-e006912.	0.8	12
81	Using simplified peer review processes to fund research: a prospective study. BMJ Open, 2015, 5, e008380.	0.8	22
82	The effects of reduced copayments on discontinuation and adherence failure to statin medication in Australia. Health Policy, 2015, 119, 620-627.	1.4	20
83	Survival of the fittest: retrospective cohort study of the longevity of Olympic medallists in the modern era. British Journal of Sports Medicine, 2015, 49, 898-902.	3.1	36
84	Patterns of Cancer Care Costs in a Country With Detailed Individual Data. Medical Care, 2015, 53, 302-309.	1.1	40
85	Association between Serum Alkaline Phosphatase and Primary Resistance to Erythropoiesis Stimulating Agents in Chronic Kidney Disease: A Secondary Analysis of the HERO Trial. Canadian Journal of Kidney Health and Disease, 2015, 2, 66.	0.6	8
86	Estimating The Potential Impact Of Insurance Expansion On Undiagnosed And Uncontrolled Chronic Conditions. Health Affairs, 2015, 34, 1554-1562.	2.5	26
87	A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial. American Journal of Kidney Diseases, 2015, 65, 49-57.	2.1	29
88	Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling. Health Technology Assessment, 2015, 19, 1-402.	1.3	30
89	Evaluating the costs and benefits of using combination therapies. Medical Journal of Australia, 2014, 200, 518-520.	0.8	17
90	Performance of the UKPDS Outcomes Model for Prediction of Myocardial Infarction and Stroke in the ADDITION-Europe Trial Cohort: Does the ADDITION Validation Add Up?. Value in Health, 2014, 17, 895-896.	0.1	1

#	Article	IF	Citations
91	Predicting mortality in people with Type 2 diabetes mellitus after major complications: a study using Swedish National Diabetes Register data. Diabetic Medicine, 2014, 31, 954-962.	1.2	21
92	Severe Hypoglycemia and Mortality After Cardiovascular Events for Type 1 Diabetic Patients in Sweden. Diabetes Care, 2014, 37, 2974-2981.	4.3	44
93	THE EFFECT OF DIABETES COMPLICATIONS ON HEALTHâ€RELATED QUALITY OF LIFE: THE IMPORTANCE OF LONGITUDINAL DATA TO ADDRESS PATIENT HETEROGENEITY. Health Economics (United Kingdom), 2014, 23, 487-500.	0.8	84
94	Forgetting to remember or remembering to forget: A study of the recall period length in health care survey questions. Journal of Health Economics, 2014, 35, 34-46.	1.3	152
95	The impact of funding deadlines on personal workloads, stress and family relationships: a qualitative study of Australian researchers. BMJ Open, 2014, 4, e004462.	0.8	46
96	A Meta-Analysis of the Relative Risk of Mortality for Type 1 Diabetes Patients Compared to the General Population: Exploring Temporal Changes in Relative Mortality. PLoS ONE, 2014, 9, e113635.	1.1	24
97	Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment â€" systematic review and modelling of progression and cost-effectiveness. Health Technology Assessment, 2014, 18, 1-128.	1.3	29
98	UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30Âyear United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia, 2013, 56, 1925-1933.	2.9	315
99	Temporal Validation of the UKPDS Outcomes Model Using 10-Year Posttrial Monitoring Data. Diabetes Care, 2013, 36, 1541-1546.	4.3	21
100	Adapting and validating diabetes simulation models across settings: Accounting for mortality differences using administrative data. Journal of Diabetes and Its Complications, 2013, 27, 351-356.	1.2	4
101	Simulating Lifetime Outcomes Associated with Complications for People with Type 1 Diabetes. Pharmacoeconomics, 2013, 31, 509-518.	1.7	10
102	On the time spent preparing grant proposals: an observational study of Australian researchers. BMJ Open, 2013, 3, e002800.	0.8	87
103	Predicting Changes in Cardiovascular Risk Factors in Type 2 Diabetes in the Post-UKPDS Era: Longitudinal Analysis of the Swedish National Diabetes Register. Journal of Diabetes Research, 2013, 2013, 1-9.	1.0	10
104	The effects of patient characteristics and geographical region on hospitalization in patients with TypeÂ2 diabetes. Diabetic Medicine, 2013, 30, 918-925.	1.2	1
105	The pricing of statins and implications for Pharmaceutical Benefits Scheme expenditure. Medical Journal of Australia, 2013, 198, 260-260.	0.8	6
106	Intergen+10: Clarifying the Crystal Ball. Australian Economic Review, 2012, 45, 325-326.	0.4	0
107	Survival of the fittest: retrospective cohort study of the longevity of Olympic medallists in the modern era. BMJ, The, 2012, 345, e8308-e8308.	3.0	75
108	â€œMirror, mirror, on the wall, who in this land is fairest of all?â€â€"Distributional sensitivity in the measurement of socioeconomic inequality of health. Journal of Health Economics, 2012, 31, 257-270.	1.3	51

#	Article	IF	Citations
109	Challenges and opportunities for the Pharmaceutical Benefits Scheme. Medical Journal of Australia, 2012, 196, 153-154.	0.8	11
110	How fair is Medicare? The income–related distribution of Medicare benefits with special focus on chronic care items. Medical Journal of Australia, 2012, 197, 625-630.	0.8	8
111	Death, Dollars and Degrees: Socio-economic Status and Longevity in Australia*. Economic Papers, 2011, 30, 348-355.	0.4	22
112	Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia. Medical Journal of Australia, 2011, 194, 52-54.	0.8	5
113	Comparability of Patient-reported Health Status. Medical Care, 2011, 49, 962-970.	1.1	14
114	A Simple Correction to Remove the Bias of the Gini Coefficient due to Grouping. Review of Economics and Statistics, 2011, 93, 982-994.	2.3	34
115	Risk equations to predict life expectancy of people with Type 2 diabetes mellitus following major complications: a study from Western Australia. Diabetic Medicine, 2011, 28, 428-435.	1.2	21
116	Changes in Inequalities of Access to Dental Care in Australia 1977-2005. Australian Economic Review, 2011, 44, 153-166.	0.4	10
117	Cutting random funding decisions. Nature, 2011, 469, 299-299.	13.7	4
118	A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation. Quality of Life Research, 2011, 20, 1669-1678.	1.5	56
119	Change in bias in self-reported body mass index in Australia between 1995 and 2008 and the evaluation of correction equations. Population Health Metrics, 2011, 9, 53.	1.3	38
120	Funding grant proposals for scientific research: retrospective analysis of scores by members of grant review panel. BMJ: British Medical Journal, 2011, 343, d4797-d4797.	2.4	96
121	Cost–effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea. Bulletin of the World Health Organization, 2011, 89, 211-220.	1.5	18
122	Simulation of Quality-Adjusted Survival in Chronic Diseases. Medical Decision Making, 2011, 31, 559-570.	1.2	7
123	Does income–related health inequality change as the population ages? Evidence from Swedish panel data. Health Economics (United Kingdom), 2010, 19, 334-349.	0.8	25
124	Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia. Medical Journal of Australia, 2010, 193, 186-187.	0.8	0
125	Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia. Medical Journal of Australia, 2010, 192, 633-636.	0.8	36
126	Cost–effectiveness of lowering blood pressure with a fixed combination of perindopril and indapamide in type 2 diabetes mellitus: an ADVANCE trial–based analysis. Medical Journal of Australia, 2010, 193, 320-324.	0.8	12

#	ARTICLE	IF	CITATIONS
127	Life Expectancy in Individuals With Type 2 Diabetes: Implications for Annuities. Medical Decision Making, 2010, 30, 409-414.	1.2	7
128	Event Rates, Hospital Utilization, and Costs Associated with Major Complications of Diabetes: A Multicountry Comparative Analysis. PLoS Medicine, 2010, 7, e1000236.	3.9	122
129	Calculating the concentration index when income is grouped. Journal of Health Economics, 2010, 29, 151-157.	1.3	27
130	Measuring achievement: Changes in risk factors for cardiovascular disease in Australia. Social Science and Medicine, 2009, 68, 552-561.	1.8	5
131	Development of life-expectancy tables for people with type 2 diabetes. European Heart Journal, 2009, 30, 834-839.	1.0	112
132	Estimating the Cost of Diabetes Mellitus-Related Events from Inpatient Admissions in Sweden Using Administrative Hospitalization Data. Pharmacoeconomics, 2009, 27, 81-90.	1.7	44
133	Using the EQ-5D Index Score as a Predictor of Outcomes in Patients With Type 2 Diabetes. Medical Care, 2009, 47, 61-68.	1.1	61
134	Estimating equations to correct self€reported height and weight: implications for prevalence of overweight and obesity in Australia. Australian and New Zealand Journal of Public Health, 2008, 32, 542-545.	0.8	43
135	Optimal recall length in survey design. Journal of Health Economics, 2008, 27, 1275-1284.	1.3	134
136	Horizontal inequities in Australia's mixed public/private health care system. Health Policy, 2008, 86, 97-108.	1.4	96
137	Estimating the Cost of Complications of Diabetes in Australia Using Administrative Health-Care Data. Value in Health, 2008, 11, 199-206.	0.1	68
138	Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial. BMJ: British Medical Journal, 2008, 336, 1177-1180.	2.4	179
139	Can Self-Rated Health Scores Be Used for Risk Prediction in Patients With Type 2 Diabetes?. Diabetes Care, 2008, 31, 795-797.	4.3	54
140	Long-Term Cost-utility Analysis of a Multidisciplinary Primary Care Diabetes Management Program in Ontario. Canadian Journal of Diabetes, 2007, 31, 205-214.	0.4	21
141	Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial. Health and Quality of Life Outcomes, 2007, 5, 21.	1.0	89
142	End-stage renal disease risk equations for Hong Kong Chinese patients with type 2 diabetes: Hong Kong Diabetes Registry. Diabetologia, 2006, 49, 2299-2308.	2.9	68
143	Factors influencing the cost of hospital care for people with diabetes in Australia. Journal of Diabetes and Its Complications, 2006, 20, 349-355.	1.2	27
144	Self-reported health: reliability and consequences for health inequality measurement. Health Economics (United Kingdom), 2006, 15, 645-652.	0.8	32

#	Article	IF	Citations
145	Assessing the Impact of Visual Acuity on Quality of Life in Individuals With Type 2 Diabetes Using the Short Form-36. Diabetes Care, 2006, 29, 1506-1511.	4.3	39
146	Estimating the Association between SF-12 Responses and EQ-5D Utility Values by Response Mapping. Medical Decision Making, 2006, 26, 18-29.	1.2	188
147	Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia, 2005, 48, 868-877.	2.9	147
148	Estimating Utility Values for Health States of Overweight and Obese Individuals Using the SF-36. Quality of Life Research, 2005, 14, 2177-2185.	1.5	59
149	A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia, 2004, 47, 1747-1759.	2.9	516
150	Missing.... presumed at random: cost-analysis of incomplete data. Health Economics (United Kingdom), 2003, 12, 377-392.	0.8	280
151	A note on the decomposition of the health concentration index. Health Economics (United Kingdom), 2003, 12, 511-516.	0.8	43
152	The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabetic Medicine, 2003, 20, 442-450.	1.2	223
153	Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). BMJ: British Medical Journal, 2002, 325, 860-860.	2.4	72
154	On the measurement of relative and absolute income-related health inequality. Social Science and Medicine, 2002, 55, 1923-1928.	1.8	114
155	Testing the convergent validity of the contingent valuation and travel cost methods in valuing the benefits of health care. Health Economics (United Kingdom), 2002, 11, 117-127.	0.8	29
156	Health Inequalities: Comparing health inequalities among men aged 18â€"65 years in Australia and England using the SFâ€36. Australian and New Zealand Journal of Public Health, 2002, 26, 136-143.	0.8	11
157	Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62). Medical Decision Making, 2002, 22, 340-349.	1.2	258
158	Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with Type II diabetes (UKPDS No. 51). Diabetologia, 2001, 44, 298-304.	2.9	90
159	An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54). Diabetic Medicine, 2001, 18, 438-444.	1.2	18
160	More or less equal? Comparing Australian income-related inequality in self-reported health with other industrialised countries. Australian and New Zealand Journal of Public Health, 2000, 24, 370-373.	0.8	15
161	Valuing the benefits of mobile mammographic screening units using the contingent valuation method. Applied Economics, 2000, 32, 1647-1655.	1.2	21
162	Costâ€"benefit analysis and mammographic screening: a travel cost approach. Journal of Health Economics, 1998, 17, 767-787.	1.3	70

#	Article	IF	Citations
163	The Bias of the Gini Coefficient Due to Grouping: Revisiting First-Order Corrections. SSRN Electronic Journal, 0, , .	0.4	4
164	Correcting the Bias in the Concentration Index When Income is Grouped. SSRN Electronic Journal, 0, , .	0.4	2
165	'Mirror, Mirror, on the Wall, Who in this Land is Fairest of All?' Distributional Sensitivity in the Measurement of Socioeconomic Inequality of Health. SSRN Electronic Journal, 0, , .	0.4	4
166	The comparative mortality of an elite group in the long run of history: an observational analysis of politicians from 11 countries. European Journal of Epidemiology, 0, , .	2.5	1
167	A randomized controlled trial to test financial incentives for COVID-19 vaccination in Ghana. Nature Medicine, 0, , .	15.2	0